Steven Hua

Steven Hua, PhD

VP, Biometrics

Steven Y. Hua is Vice President of Biometrics. He brings over 25 years of life science experience to Kezar and works to build/oversee the Biometrics organization with responsibility for study designs, data management, data analysis and results interpretation, and collaboration with partner functions in Development, Research and Medical Affairs.

Before joining Kezar, Steven served as Sr. Director of Biostatistics at Celgene Corp (acquired by Bristol Myers Squibb in 2019), where he led the statistical support for multiple late-stage trials in gastrointestinal indications, including regulatory submissions and approval of Zeposia® (ozanimod) for ulcerative colitis.

Prior to Celgene, Steven was a director of Biostatistics at Pfizer, where he led and contributed to strategic planning and execution for product life-cycle management and new indications (hematology, oncology, immuno-oncology, rheumatoid arthritis, and neurology), successful regulatory submissions with approvals, clinical development, data integration/ standardization, resource needs and timeline acceleration.

Steven also held various roles at Wyeth Pharmaceuticals, Allergan, Alcon Laboratories, Abbott Laboratory, and Johnson & Johnson Medical, supporting clinical programs and regulatory interactions in various therapeutic areas.

Steven received PhD degree in statistics from University of Texas at Arlington, MS degree in Biostatistics from University of Illinois at Chicago.